Online inquiry

IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12409MR)

This product GTTS-WQ12409MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Crohn's disease (CD), Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ12409MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3127MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ8085MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ1460MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ10097MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LA480
GTTS-WQ12447MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ13845MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ9004MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ821MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-085
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW